Related by context. All words. (Click for frequent words.) 70 pharmacokinetic 70 preclinical efficacy 69 vitro experiments 68 Phase 1b trial 67 Phase 2b study 67 Phase IIa trial 67 ascending doses 67 nonclinical studies 67 GLP toxicology studies 67 cannabinor 66 multiple ascending dose 66 pharmacodynamic PD 66 Phase 2a trial 66 Phase IIB 66 pharmacodynamic effects 66 pharmacokinetic PK 66 pharmacokinetics PK 66 placebo controlled studies 66 phase 2a 66 Phase #b/#a 65 Phase Ib study 65 Phase Ib clinical 65 prucalopride 65 riociguat 65 pharmacokinetics 65 pharmacokinetic parameters 65 APTIVUS 65 clinical pharmacology studies 65 pharmacokinetic PK study 65 multicenter Phase II 65 oral rivaroxaban 65 Phase IIa 65 phase Ib 65 Phase Ib 65 placebo controlled clinical trials 65 single ascending dose 64 pharmacokinetic characteristics 64 phase IIa 64 bioequivalence studies 64 Phase 1a 64 PSN# [002] 64 Phase 1a clinical 64 favorable pharmacokinetic profile 64 ascending dose 64 Tracleer R 64 urocortin 2 64 dose escalation Phase 64 ruxolitinib 64 maximally tolerated dose 64 phase IIb 64 Dacogen injection 64 AZILECT R 64 pharmacokinetic pharmacodynamic 64 carcinogenicity studies 64 Anthim 64 injectable formulations 64 preclinically 64 preclinical toxicology 64 Phase 2a clinical 64 CANCIDAS 64 Phase IIIb study 63 Phase Ia 63 Zavesca R 63 active comparator 63 IND submission 63 Phase IIb trials 63 GAMMAGARD 63 budesonide foam 63 pharmacodynamic properties 63 RSD# oral 63 orally dosed 63 placebo controlled trials 63 preclinical pharmacokinetic 63 vitro studies 63 Phase IIa trials 63 H#N# VLP vaccine 63 JAK inhibitor 63 Phase 2a 63 pharmacokinetic PK profile 63 preclinical pharmacology 63 Phase 1b clinical 63 phase IIb III 63 dosing cohort 63 subgroup analyzes 63 dose cohort 63 rBChE 63 trodusquemine 63 pharmacodynamics 62 phase IIIb 62 Phase IIb clinical trials 62 fosbretabulin 62 NP2 Enkephalin 62 oral prodrug 62 NEBIDO 62 Prodarsan ® 62 phase IIa clinical 62 Phase 2b trial 62 NOX E# 62 placebo controlled Phase 62 pharmacodynamic 62 posaconazole 62 Capesaris 62 pDNA vaccine 62 MGN# 62 Menerba 62 bicifadine 62 Increlex R 62 preclinical studies 62 Phase IIIb clinical 62 Phase IIb trial 62 Valortim ® 62 teriflunomide 62 ADAGIO study 62 thorough QT 62 ADVANCE PD 62 indiplon capsules 62 phase IIb trial 62 carcinogenicity study 62 viral kinetic 62 HCV SPRINT 62 pharmacokinetic profiles 62 dosing cohorts 62 Phase 1b 62 PRTX 62 Phase Ib II 62 dose escalation trial 62 Azedra 62 fluoroquinolone antibiotic 62 Pharmacokinetic 62 LB# [003] 62 pitavastatin 62 toxicological studies 62 randomized controlled clinical trials 62 lomitapide 62 solithromycin 62 tolerability profile 62 brivaracetam 62 INT# [002] 62 pharmacodynamic profile 62 micafungin 62 demonstrated antitumor activity 61 Phase IIa clinical 61 Phase IIa clinical trials 61 GFT# 61 Tarceva TM 61 forodesine 61 ORMD 61 topical formulations 61 teduglutide 61 torezolid phosphate 61 AZILECT ® 61 Valortim R 61 MERLIN TIMI 61 PROCHYMAL 61 Kahalalide F 61 vidofludimus 61 Phase III trials 61 confirmatory Phase III 61 pharmacodynamic parameters 61 S/GSK# 61 tolevamer 61 Altastaph 61 BLA submission 61 nalbuphine ER 61 vivo assays 61 desvenlafaxine succinate 61 nitazoxanide 61 Spiegelmer ® 61 YONDELIS 61 elotuzumab 61 lucinactant 61 liprotamase 61 glatiramer acetate 61 PREOS 61 Triolex 61 Poly ICLC 61 Increlex ® 61 OvaRex ® MAb 61 randomized multicenter Phase III 61 phase IIb clinical 61 Phase #/#a 61 inecalcitol 61 Phase IIb III 61 ganetespib 61 Traficet EN 61 bioequivalence 61 GHRH 61 FOSRENOL R 61 CELVAPAN H#N# 61 randomized Phase 2b 61 intravenously administered 61 IMA# 61 Phase IIIb 61 liposomal formulation 61 bortezomib Velcade 61 DCCR 61 phase IIb study 61 Phase IIb clinical 61 pharmacokinetic profile 61 randomized Phase IIb 61 RiVax 61 plasma kallikrein inhibitor 61 celgosivir 61 Thiovir 61 lanreotide 61 TMC# [002] 61 GAP #B# 61 clinical trials 61 EMBEDA ™ 61 Phase IIb 61 Dyloject TM 61 ORENCIA ® 60 Valortim 60 HuMax EGFr 60 tolerability profiles 60 AeroLEF TM 60 Phase 2b clinical trials 60 MAA submission 60 HGS# 60 Arikace 60 SILENOR TM 60 RE SURGE 60 balsalazide tablet 60 RezularTM 60 crizotinib PF # 60 placebo controlled clinical 60 GRNVAC1 60 Preclinical studies 60 GSK# [002] 60 omega interferon 60 dose cohorts 60 administered subcutaneously 60 enzastaurin 60 viral kinetics 60 CIMZIA TM 60 ORENCIA R 60 caspofungin 60 Augment Injectable 60 pomalidomide 60 clinical trial 60 AEG# 60 ROTARIX 60 OMP #M# 60 Phase Ib clinical trials 60 NN# [001] 60 #D#C# 60 Zoraxel 60 mcg dose 60 tigecycline 60 Candesartan 60 dose proportionality 60 Bezielle 60 radezolid 60 ARIKACE 60 Phase 2b 60 CG# [003] 60 selective modulator 60 R#/MEM # 60 midstage trials 60 ganaxolone 60 AEGR 60 CR# vcMMAE 60 dosing regimens 60 LT NS# 60 vivo preclinical 60 RSD# 60 Homspera 60 NXL# 60 fluvastatin 60 UPLYSO 60 #mg dose [001] 60 methylnaltrexone 60 pharmacokinetics pharmacodynamics 60 anti leukemic 60 NEUMUNE 60 SILENOR 60 PROMACTA 60 PXD# 60 pharmacodynamic markers 60 pramlintide metreleptin combination 60 Ventavis ® 60 registrational 60 Phase III Clinical Trials 60 NDA resubmission 60 Phase III clinical trials 60 Ozarelix 60 intranasal formulation 60 Phase 2b clinical 60 lanthanum carbonate 60 Anticalins ® 60 RAV# 60 BNC# 60 Civacir 60 oritavancin 60 ATL# [001] 60 dose escalation study 60 histamine dihydrochloride 60 Onrigin 60 Pharmacokinetic PK 60 genotypic resistance 60 NGX# 60 BioVant 60 AZX# 60 rALLy trial 60 Phase IIA 60 pradefovir 60 CORT # 60 NO# [002] 60 PRIMO CABG 60 PDE4 inhibitor 60 MAGE A3 ASCI 60 ELACYT 60 mapatumumab 60 multicenter trials 60 indibulin 60 mg kg BID 60 vivo toxicology 60 Proquin XR 60 masitinib 60 plasma pharmacokinetics 60 Sym# 60 randomized Phase III 60 Clolar ® 60 Phase #b/#a trial 60 multicenter Phase 60 Androxal TM 60 pramlintide 60 pivotal bioequivalence 60 Myocet 59 treatment naive genotype 59 antiviral efficacy 59 CRLX# 59 PRT# 59 ENMD # 59 tolerability 59 inhibitor RG# 59 multidose 59 ISIS # 59 metabolic parameters 59 prospective observational 59 intermittent dosing 59 DermaVir Patch 59 bovine thrombin 59 EDEMA3 trial 59 Thorough QT 59 GLPG# 59 BRIM3 59 tramiprosate Alzhemed TM 59 salmeterol fluticasone 59 coadministration 59 adipiplon 59 IPLEX 59 ceftazidime 59 trabectedin 59 Amigal 59 histone deacetylase inhibitor 59 pafuramidine 59 Phase 1b clinical trials 59 HGS ETR2 59 bioequivalency 59 CIMZIA ™ 59 miconazole Lauriad ® 59 Egrifta 59 Afatinib 59 Vernakalant 59 BLA filing 59 RE LY trial 59 CLORETAZINE TM VNP#M 59 daily subcutaneous injections 59 blinded randomized placebo controlled 59 SCH # 59 fluticasone furoate 59 COMFORT II 59 BrachySil 59 GnRH antagonist 59 PHX# 59 depsipeptide 59 ALTU 59 sulodexide 59 inhaled AAT 59 retapamulin 59 cynomolgus monkeys 59 receptor tyrosine kinase inhibitor 59 dose escalation 59 CaPre TM 59 eprotirome 59 oxymorphone ER 59 DXL# 59 dalbavancin 59 orally bioavailable 59 C1 INH 59 Proellex TM 59 OHR/AVR# 59 Cethromycin 59 Cloretazine 59 neratinib 59 Carfilzomib 59 XmAb# 59 Pharmacokinetics PK 59 nelfinavir 59 BeneFIX 59 orBec 59 intravenous dosing 59 Betaferon ® 59 Blinatumomab 59 double blinded placebo 59 Phase III clinical 59 Plenaxis TM 59 secondary efficacy endpoints 59 EOquin TM 59 oral ridaforolimus 59 eculizumab therapy 59 JAK Inhibitor 59 PREOS R 59 TOLAMBA 59 pharmacodynamics PD 59 IDX# 59 subcutaneously administered 59 SparVax TM 59 safety tolerability pharmacokinetic 59 Plicera 59 TYGACIL 59 INCB# [001] 59 acyclovir Lauriad ® 59 efficacy tolerability 59 Ophena TM 59 registrational trial 59 Viramidine 59 BAL# [002] 59 faropenem 59 basal bolus regimen 59 LIALDA 59 IFN Beta 59 antiviral activity 59 delafloxacin 59 ALVESCO HFA 59 Tekturna HCT 59 alvimopan 59 TQT studies 59 Hycamtin 59 Raptiva ® 59 HGS ETR1 59 polymerase inhibitor 59 safety tolerability pharmacokinetics 59 cardioprotective effects 59 Prosaptide 59 placebo controlled 59 GSK# [001] 59 REYATAZ R 59 davunetide intranasal AL 59 Xanafide 59 miglustat 59 Alvesco R 59 Icatibant 59 alvespimycin 59 Mipomersen 59 Triapine R 59 Pafuramidine 59 Cimzia ® certolizumab pegol 59 PEG IFN 59 ZD# [001] 59 Valdoxan 59 EOquin 59 mertansine 59 Tanespimycin 59 Valtropin 59 ONGLYZA ™ 59 Degarelix 59 GALNS 59 BCX# 59 apricitabine 59 valopicitabine 59 Onconase 59 Aquavan Injection 59 HCV replicon 59 rhGH 59 TMC# C# 59 ProLindac 59 SNT MC# 59 Quinamed 59 #mg dose [002] 59 QNEXA 59 candidates Dyloject TM 59 ALGRX 59 EXPAREL ™ 59 multicenter phase 59 INTERCEPT platelets 59 daptomycin 59 dosage regimens 59 #I TM# 59 APTIVUS r 59 SPIRIVA HandiHaler 59 Ereska 59 velafermin 59 PD LID 59 CAELYX 59 MIRCERA 59 GLYX 59 diabetic neuropathic pain 59 PROSTVAC TM 59 mcg doses 59 Elitek 59 Saforis 59 EndoTAG TM -1 59 efalizumab 59 Pimavanserin 59 ibandronate 59 aripiprazole Abilify 58 TH# [003] 58 mg kg cohorts 58 Aplidin 58 TPI ASM8 58 inhaled iloprost 58 PYY3 58 dose dose escalation 58 hGH CTP 58 Vidaza azacitidine 58 investigational humanized monoclonal antibody 58 tramiprosate 58 PK PD 58 IIa trial 58 standard chemotherapy regimen 58 Actilon 58 PS# [001] 58 galiximab 58 RhuDex ® 58 HAART regimens 58 PYY #-# 58 CERVARIX 58 randomized multicenter trial 58 pharmacodynamic endpoints 58 HspE7 58 Alzhemed TM 58 elacytarabine 58 TRIOLEX 58 nab paclitaxel 58 ASSERT trial 58 Aclidinium 58 dose escalation clinical 58 Multiple Ascending Dose 58 PEGPH# 58 Focalin XR 58 orally administered 58 intranasal delivery 58 antiepileptics 58 QD dosing 58 nanoviricides 58 HCV RESPOND 2 58 clevidipine 58 Cleviprex TM clevidipine 58 nebulized formoterol fumarate 58 cMET 58 ZYBRESTAT fosbretabulin 58 SABCS 58 PhG alpha 1 58 dose titration 58 receptor inhibitor 58 efficacy 58 ThGRF 58 therapeutic regimens 58 busulfan 58 ritonavir boosted 58 Vilazodone 58 GLP toxicology 58 mycophenolate mofetil MMF 58 AMD# [003] 58 pioglitazone HCl 58 protease inhibitor PI 58 rFIXFc 58 Granulocyte Colony Stimulating Factor 58 CoFactor 58 LCP Tacro ™ 58 MEND CABG 58 Solorel TM 58 ISENTRESS 58 Neulasta ® 58 Kamada AAT 58 piroxicam 58 Anturol TM 58 anidulafungin 58 nucleotide analog 58 antidepressant efficacy 58 LymphoStat B TM 58 metaanalysis 58 anticancer agent 58 Phase 2a clinical trials 58 sNDA submission 58 guanfacine extended release 58 Mylotarg 58 LY# [003] 58 rindopepimut 58 HQK 58 Exforge HCT 58 low dose cytarabine 58 piperacillin tazobactam 58 trastuzumab emtansine T DM1 58 Privigen 58 ocular formulation 58 AIR CF1 58 rALLy clinical trial 58 biologic DMARD 58 ACOMPLIA R 58 CIMZIA TM certolizumab pegol 58 oral bioavailability 58 subcutaneous dosing 58 generation purine nucleoside 58 pharmacokinetic equivalence 58 trivalent influenza vaccine 58 amrubicin 58 IMC A# 58 calcitonin 58 Dacogen decitabine 58 vivo validation 58 PEARL SC 58 meropenem 58 oral FTY# 58 ritonavir boosting 58 bendamustine 58 Protexia R 58 Prodarsan 58 TELINTRA 58 VIR# 58 Lovaxin C 58 TACI Ig 58 randomized clinical trials 58 sunitinib malate 58 Dalbavancin 58 fumagillin nanoparticles 58 Phase III Clinical Trial 58 Glatiramer Acetate 58 zileuton 58 CEQ# 58 axitinib 58 Inhalation Solution 58 LEUKINE 58 LCP AtorFen 58 TRO# 58 dyskinesia PD LID 58 Hizentra 58 ARIKACE ™ 58 immunogenicity 58 omecamtiv mecarbil 58 RoACTEMRA 58 PROPEL trial 58 prasterone 58 investigational protease inhibitor 58 LEXIVA r 58 preclinical 58 TBC# 58 Multimeric 58 HyQ 58 ChronVac C R 58 interferon gamma 1b 58 multicenter randomized placebo controlled 58 PREZISTA r 58 EVIZON 58 rilpivirine 58 Phase #/#a trial 58 Meta analyzes 58 Cethrin R 58 FOLOTYN ® 58 Onrigin TM 58 docetaxel Taxotere 58 tipranavir 58 systemically administered 58 ALISTA 58 liposomal amphotericin B 58 blinded placebo controlled 58 rilonacept 58 Crofelemer 58 Amrubicin 58 FluCide 58 double blinded randomized 58 LibiGel Phase III 58 incyclinide 58 EXPAREL 58 telaprevir VX 58 AIR2 Trial 58 ISTODAX 58 canakinumab 58 Pharmacokinetic studies 58 Ostarine 58 varespladib 58 Study GL# 58 EmbraceAC 58 Loramyc R 58 peginterferon alpha 2a 58 GRN# 58 trials RCTs 58 VNP#M 58 pivotal Phase III 58 C1 inhibitor rhC1INH 58 fidaxomicin Phase 3 58 huC# DM4 58 CCR5 antagonist 58 MGd 58 administered intranasally 58 arbaclofen 58 albinterferon alfa 2b 58 Safinamide 58 HuMax CD4 58 Serdolect ® 58 octreotide 58 elagolix 58 NATRECOR ® 58 denufosol 58 octreotide implant 58 confirmatory clinical 58 EMEND 58 CIP TRAMADOL ER 58 midstage clinical 58 Prodarsan R 58 DermaVir 58 alagebrium 58 cinacalcet 58 JAK#/JAK# inhibitor 58 Angiolix 58 TREDAPTIVE 58 zileuton CR 58 BMS# 58 Cloretazine R VNP#M 58 Velcade bortezomib 58 DR Cysteamine 58 GOUT 58 tesofensine 58 torsemide ER 58 antitumor effects 58 ongoing Phase 1b 58 decitabine 58 DAVANAT 58 Darunavir 58 Neurodex 58 rFSH 58 Teysuno 58 GTC recombinant human 58 PEG SN# 58 highly immunogenic 58 Radezolid 58 IFN β 57 PMA submission 57 Phase III 57 miconazole 57 randomized controlled Phase 57 rhFVIIa 57 oral deforolimus 57 Mycophenolate Mofetil 57 NOXAFIL 57 goserelin 57 Eligen R B# 57 #mg dose [003] 57 Protelos 57 ONTAK 57 docetaxel chemotherapy 57 IMP# 57 multicenter clinical trials 57 biodistribution studies 57 oral salmon calcitonin 57 Tamibarotene 57 Chrysalin 57 Microplasmin 57 PA# [002] 57 statistically significant efficacy 57 Relivar 57 bazedoxifene conjugated estrogens 57 analgesic efficacy 57 DepoDur TM 57 virus HCV protease inhibitor 57 Apoptone 57 GAMMAGARD LIQUID 57 SomatoKine 57 EGS# 57 somatostatin analogues 57 paricalcitol 57 dacetuzumab 57 QLT# 57 relapsed MM 57 TDF FTC 57 SinuNase TM 57 Omacetaxine mepesuccinate 57 NDA submission 57 THALOMID 57 Pemetrexed 57 Dapagliflozin 57 CDP# 57 tipifarnib 57 danoprevir 57 FDA Approvable Letter 57 AVERROES 57 LEP ETU 57 isavuconazole 57 mg kg dose 57 NEUGENE antisense 57 astemizole 57 refractory CLL 57 dosed orally 57 lisdexamfetamine dimesylate 57 Radilex 57 steroid dexamethasone 57 EDEMA3 57 genotypic 57 ONGLYZA 57 Allovectin 7 ® 57 oral iron chelator 57 Dose escalation 57 sorafenib Nexavar 57 Gattex 57 Elagolix 57 DDP# 57 Exherin TM 57 FOSRENOL ® 57 Genz # 57 efficacy endpoints 57 nonrandomized 57 TOCOSOL Paclitaxel 57 4CMenB 57 MYCAMINE 57 pegylated 57 Filgrastim 57 CCR5 inhibitor 57 JAK inhibitors 57 thalidomide Thalomid 57 dextofisopam 57 trospium 57 Zenvia Phase III 57 serotonin norepinephrine reuptake inhibitor 57 Epoetin alfa 57 intravitreal injection 57 CDK inhibitor 57 ganciclovir 57 masked placebo controlled 57 Solorel 57 ASONEP 57 HepaGam B 57 ONTARGET 57 antineoplastic 57 cediranib 57 pharmacoeconomic analysis 57 Aurora kinase inhibitor 57 pegylated recombinant 57 NUVIGIL 57 Phase lll 57 torezolid 57 Xelox 57 trastuzumab Herceptin ® 57 ALB # 57 Glybera R 57 Aurexis 57 AZILECT 57 Ophena 57 Fentanyl TAIFUN R 57 Iloperidone 57 ATACAND 57 Lenocta 57 AVN# [001] 57 Q#IR 57 methotrexate therapy 57 Alphanate R 57 blinded randomized 57 bolus injection 57 Emselex 57 bifeprunox 57 alicaforsen enema 57 PEG Interferon lambda 57 optimal dosing 57 Teriparatide 57 IIa trials 57 GEM OS2 57 sitagliptin 57 ataluren 57 BEXXAR 57 Fodosine 57 Tolvaptan 57 thymalfasin 57 Chemophase 57 ACCLAIM II 57 CLL8 57 aclidinium bromide 57 Tyrima 57 OvaRex R 57 Engerix B 57 Cloretazine ® 57 Pennsaid R 57 MGCD# [001] 57 optimal dosing regimens 57 Natural S equol 57 Orazol 57 Archexin 57 Stimuvax R 57 visilizumab 57 Dual Opioid 57 Ampligen ® 57 LC#m# 57 Protexia ® 57 Seliciclib 57 ponatinib 57 microdose 57 adalimumab 57 Belerofon 57 Protectan CBLB# 57 divalproex sodium 57 mifamurtide 57 LEVAQUIN ® 57 DASISION 57 tasimelteon 57 Urocidin 57 triphendiol 57 SUCCEED trial 57 Arranon 57 INGN 57 Elocalcitol 57 Flutiform TM 57 Nebido 57 RGB # 57 neuroprotective properties 57 multicenter placebo controlled 57 ASCEND HF 57 Phase III Pivotal 57 Nasulin 57 Telintra 57 prospectively defined 57 GLP1 agonist 57 OncoVEX GM CSF 57 CTAP# Capsules 57 fenofibric acid 57 PLX cells 57 CA4P 57 darunavir ritonavir 57 HCV protease inhibitors 57 nucleotide analogue 57 Histalean TM 57 Keppra ® levetiracetam 57 mg RDEA# 57 pertuzumab 57 VivaGel TM 57 LUNESTA TM 57 retaspimycin 57 PCK# 57 CCR5 mAb 57 MORAb 57 Onbrez Breezhaler 57 Sanofi Pasteur Fluzone 57 gallium nitrate 57 placebo controlled randomized 57 octreotide acetate 57 LCP Tacro 57 #beta estradiol 57 pegylated liposomal doxorubicin 57 Humate P 57 acyclovir Lauriad R 57 immunotherapeutic vaccine 57 QTc prolongation 57 KRAS status 57 Interferon alpha 57 tanespimycin 57 uricase 57 HuMax CD# 57 REMINYL ® 57 Calcitonin 57 efficacy endpoint 57 REMUNE R 57 midstage clinical trials 57 vivo efficacy 57 mg/m2 dose 57 Cimzia TM 57 darunavir r 57 CRD5 57 AEZS 57 antifolates 57 ATL# [002] 57 MAS XR 57 immune modulatory 57 TLK# 57 pharmacokinetic interactions 57 R#/MEM 57 MERIT ES 57 PRECiSE 57 dexpramipexole 57 cariprazine 57 ICH guidelines 57 Phase 2b kidney transplant 57 huN# DM1 57 Japanese Encephalitis vaccine 57 OncoVEX 57 synthetic retinoid 57 Azacitidine 57 topically administered 57 randomized crossover 57 Apo AI Milano 57 prospective randomized multicenter 57 Truvada tablets 57 PPAR gamma agonist 57 UVIDEM 57 vismodegib 57 MenACWY 57 antitumour activity 57 REVLIMID lenalidomide 57 INC# 57 macrolide antibiotic 57 RAPAFLO